摘要
在世界范围内,尘螨是最常见的吸入性过敏原,可诱发过敏性鼻炎、过敏性哮喘、特应性皮炎等过敏性疾病,对患者的工作和生活造成极大影响。尘螨特异性免疫治疗是目前唯一针对病因的治疗,许多临床研究以及Meta分析均证实特异性免疫治疗对于过敏性疾病,尤其是过敏性鼻炎具有良好临床疗效。除了可有效缓解临床症状、减少临床用药外,更重要的是能够阻断疾病的自然进程,预防鼻炎进展为哮喘。特异性免疫治疗前后许多免疫学及生物学指标可发生变化,为客观评价免疫治疗的疗效提供了依据。多项研究显示,尘螨特异性免疫治疗前后尘螨的致敏蛋白组分也可发生变化,使得尘螨组分蛋白可能成为评估特异性免疫治疗的疗效指标,本文将对这一领域的研究进展进行综述。
Dust mites are the most common inhalation allergen over the world,which can induce allergic diseases such as allergic asthma,allergic rhinitis and atopic dermatitis.These conditions can have a great impact on patients'quality of life.At present,dust mite specific immunotherapy is the only available treatment targeting its etiology.Many clinical studies and meta analyses have confirmed that specific immunotherapy has a good clinical effect on allergic diseases,especially allergic rhinitis.In addition to effectively relieving clinical symptoms and reducing clinical medication,more importantly,it can block the natural process of allergic diseases and prevent rhinitis from developing into asthma.The changes of many immunological and biological indexes before and after specific immunotherapy provide a foundation for objectively evaluating the efficacy of immunotherapy.A number of studies have shown that the allergenic protein components of dust mites can be changed before and after specific immunotherapy,so that dust mite component proteins may become an index to evaluate the efficacy of specific immunotherapy.This paper reviews the research progress in this field.
作者
丁佳琪
王晓艳
王学艳
尹金淑
DING Jiaqi;WANG Xiaoyan;WANG Xueyan;YIN Jinshu(Otolaryngology Head and Neck Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China;Allergic Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China)
出处
《标记免疫分析与临床》
CAS
2021年第2期348-352,共5页
Labeled Immunoassays and Clinical Medicine
基金
北京市医管中心扬帆计划(编号:ZYLX201826)。
关键词
尘螨
特异性免疫治疗
蛋白组分
过敏性鼻炎
Dust mite
Specific immunotherapy
Protein component
Allergic rhinitis
作者简介
通讯作者:尹金淑,E-mail:yinjinshu55@aliyun.com。
